Global Oncology Biosimilar Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Disease Indication;

Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, and Others.

By Drug Type;

mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others.

By Distribution Channel;

Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn308825095 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Oncology Biosimilar Market (USD Million), 2021 - 2031

In the year 2024, the Global Oncology Biosimilar Market was valued at USD 5,107.57 million. The size of this market is expected to increase to USD 61,846.01 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 42.8%.

The global oncology biosimilar market has been steadily expanding, driven by the increasing demand for cost-effective alternatives to expensive biologic drugs used in cancer treatment. Biosimilars offer a promising avenue to alleviate the economic burden of cancer care while maintaining therapeutic efficacy. With the expiration of patents for several blockbuster biologics, including monoclonal antibodies and therapeutic proteins, pharmaceutical companies are seizing the opportunity to develop biosimilar versions. This trend has fueled competition in the oncology market, resulting in greater accessibility to life-saving treatments for patients worldwide.

In recent years, regulatory agencies such as the FDA and EMA have established robust frameworks for the approval of biosimilars, ensuring rigorous testing to demonstrate similarity in terms of efficacy, safety, and quality compared to their reference biologics. This regulatory clarity has instilled confidence among healthcare providers and patients, further propelling the adoption of oncology biosimilars. Moreover, favorable reimbursement policies and incentives offered by governments and healthcare organizations have incentivized the utilization of biosimilars, driving down treatment costs and widening patient access to innovative cancer therapies.

The oncology biosimilar landscape is witnessing dynamic shifts, with several key players strategically investing in research and development to expand their biosimilar portfolios. Collaborations and partnerships between pharmaceutical companies and biotechnology firms are becoming increasingly common, leveraging complementary expertise to accelerate biosimilar development and commercialization. Additionally, advancements in bioprocessing technologies and manufacturing capabilities have enhanced the scalability and efficiency of biosimilar production, further driving down costs and increasing market competitiveness.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Disease Indication
    2. Market Snapshot, By Drug Type
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Oncology Biosimilar Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Cost-effectiveness
        2. Expanding oncology drug market
      2. Restraints
        1. Regulatory hurdles
        2. Complex manufacturing processes
      3. Opportunities
        1. Increasing demand for cancer treatment
        2. Emerging markets potential
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Oncology Biosimilar Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Breast Cancer
      2. Colorectal Cancer
      3. Blood Cancer
      4. Neutropenia Cancer
      5. Non-Small Cell Lung Cancer
      6. Others
    2. Global Oncology Biosimilar Market, By Drug Type, 2021 - 2031 (USD Million)
      1. mAb
      2. Immunomodulators
      3. Hematopoietic Agents
      4. G-CSF
      5. Others
    3. Global Oncology Biosimilar Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Retail Pharmacies
      2. Hospital Pharmacy
      3. Online Pharmacy
    4. Global Oncology Biosimilar Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Amgen Inc.
      2. Pfizer Inc.
      3. Celltrion Inc.
      4. Biocon Ltd.
      5. Mylan N.V.
      6. Teva Pharmaceutical Industries Ltd.
      7. Samsung Bioepis Co., Ltd.
      8. Sandoz International GmbH
      9. Merck & Co., Inc.
      10. Dr. Reddy's Laboratories Ltd.
  7. Analyst Views
  8. Future Outlook of the Market